Compare DexCom, Inc. (DXCM) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Marvell Technology Inc — how do they compare? DexCom, Inc. trades at $77.92 (market cap $28.06B), while Marvell Technology Inc trades at $187.91 (market cap $181.05B). The key difference: Marvell Technology Inc is far larger — about 6.5× DexCom, Inc.'s market cap, and Marvell Technology Inc pays a 0.12% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MRVL | |
|---|---|---|
Market Cap | $28.06B | $181.05B |
Sector | Health | Technology |
52-Week High | $89.53 | $316.43 |
52-Week Low | $54.84 | $62.31 |
Enterprise Value | $27.03B | $182.48B |
Dividend Yield | — | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Marvell Technology (MRVL) trades at $187.77, down 15.59% in the past 24 hours, reflecting recent market volatility. The stock shows strong analyst support with an 82.19% buy rating and a consensus price target of $275.68. Recent earnings beats and projected revenue growth to $8.7B in 2026 highlight fundamental strength, though high valuation ratios like a P/E of 70.88 and negative net income in 2025 pose concerns. Technical indicators are mixed, with oscillators bullish but moving averages bearish, and key support at $183.
The outlook for MRVL is cautiously optimistic, driven by AI infrastructure demand and custom chip growth opportunities. Risks include competitive pressures, execution challenges, and high debt levels. Investors should weigh the strong analyst consensus against valuation premiums and near-term profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
